EnVivo Pharmaceuticals, Inc. to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease

WATERTOWN, Mass., July 7 /PRNewswire/ --

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information about EnVivo, visit www.envivopharma.com.

CONTACT: Michael Aalto, Media Relations for EnVivo Pharmaceuticals,
+1-617-563-9462

Web site: http://www.envivopharma.com/